|May 17, 2012|
Susa Coffey, MD, HIV InSite Medical Editor
| Fosamprenavir |
The U.S. Food and Drug Administration has extended approval of fosamprenavir to include children 4 weeks of age and older, and has announced dosing recommendations for use of fosamprenavir oral suspension in young children.
For children who are naive to PIs, fosamprenavir may be used at age 4 weeks and older, but for PI-experienced children, fosamprenavir should not be used until age 6 months or older. Additionally, coadministration with ritonavir is recommended for all children <2 years of age, and twice-daily dosing is recommended for all children.
For specific dosage information, see the Lexiva package label.
The U.S. Food and Drug Administration has approved etravirine for use in treatment-experienced children 6 years of age and older who have HIV strains that are resistant to an NNRTI and to other ARVs. Pediatric dosing is based on weight, and children must weigh at least 16 kg. A 25 mg tablet is now available for pediatric use.
For specific dosage information, see the Intelence package label.